Feb 28, 2018 – Nasdaq (Nasdaq: NDAQ) announces that trading in BBS-Bioactive Bone Substitutes Plc shares (short name: BONEH) commence today on Nasdaq First North Finland. The company’s shares will also be listed on Nasdaq First North Sweden on the same date (short name: BONES).The company belongs to the Health care sector. BBS-Bioactive Bone Substitutes is the 8th company to be admitted to trading on Nasdaq’s Nordic markets* in 2018, and it represents the 2nd listing on Nasdaq Helsinki in 2018.

BBS-Bioactive Bone Substitutes Plc (”BBS”) is a Finnish health technology company that has developed a new generation innovative medical device product for the treatment of bone defects in orthopaedic and traumatological surgery. The Company has no turnover. BBS-Bioactive Bone Substitutes Plc was established in 2003. A seven-year product development project at the University of Oulu preceded the establishment of the Company. The Company’s domicile is Oulu, and it has 12 employees. The Company also has a scientific advisory board consisting of medical experts. The Company has an authorised production facility for bone protein extract and is in the process of obtaining ISO 13485 certification for the ARTEBONE® implant production line. The Company’s first product ARTEBONE® is an injectable paste in a ready-to-use syringe, injected into the bone’s problem spot or fracture area. It is designed to promote the natural healing of the bone by utilising growth factors extracted from reindeer bone and tricalcium phosphate (TCP) ceramics that act as a base for bone formation. All of the preclinical testing and clinical tests have been done, and the Company has launched the application process for the CE mark. The CE mark is a prerequisite for the commercialisation of ARTEBONE® in the EU area. ARTEBONE®’s benefit is that it reduces expensive operating room time compared to the use of the patient’s own bone and speeds up the patient’s recovery time, as well as reducing treatment costs.  For more information: www.bbs-artebone.fi.

”We wish the over 1,100 new shareholders welcome to our company. The company is now focusing on the finalization of the application process of the sales license and the marketing.  Turbulence in the Stock Market at the Launch had an impact on the result of the IPO but considering the conditions we are anyway happy with the IPO”, says CEO Pekka Jalovaara of BBS-Bioactive Bone Substitutes.

“We would like to extend a warm welcome to BBS-Bioactive Bones Substitutes which is an interesting addition to our First North market both in Finland and Sweden. We congratulate the company on the completion of its IPO and look forward to a lasting partnership with the company and its shareholders”, said Henrik Husman, President of Nasdaq Helsinki.

BBS-Bioactive Bone Substitutes Plc has appointed Aalto Capital Partners Oy as its Certified Adviser in Finland and Stockholm Certified Advisors AB as its Certified Advisor in Sweden.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm


About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion. To learn more, visit: http://business.nasdaq.com

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

 

FOR  MEDIA RELATIONS:
Maarit Bystedt
tel. +358(0)9 6166 7274
maarit.bystedt@nasdaq.com